^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Topoisomerase I inhibitor

    Related drugs:
    1d
    Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches. (PubMed, Clin Transl Sci)
    Simulations suggested that Dato-DXd at 6 mg/kg Q3W provide superior tumor control and improved PFS compared to a lower dose in patients with HR+/HER2- BC. This work underscores the importance of integrating advanced modeling techniques into the dose optimization paradigm.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Datroway (datopotamab deruxtecan-dlnk)
    1d
    Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. (PubMed, Gynecol Oncol)
    T-DXd showed remarkable preclinical activity against HER2 FISH-negative, IHC-low EEC both in-vitro and in-vivo. These findings support its use beyond HER2-high expression and may represent a novel and effective treatment option for patients with HER2-low EEC who have progressed on standard chemotherapy and immunotherapy.
    Preclinical • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    A Study of ZL-1310 in Participants With Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Zai Lab (Shanghai) Co., Ltd. | N=86 --> 112 | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Aug 2027
    Enrollment change • Trial completion date • Trial primary completion date
    3d
    OptiTROP-Lung03: SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=321, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR wild-type • ALK fusion • MET mutation
    |
    docetaxel • Jiataile (sacituzumab tirumotecan)
    3d
    A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • EGFR expression • EGFR positive • EGFR negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • SYS6010
    3d
    CHIMERA: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. (clinicaltrials.gov)
    P2, N=42, Recruiting, Gruppo Oncologico del Nord-Ovest
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    3d
    SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov)
    P2, N=258, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active, not recruiting --> Recruiting | N=76 --> 258 | Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • AiRuiLi (adebrelimab)
    3d
    Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (clinicaltrials.gov)
    P1, N=35, Recruiting, National Cancer Institute (NCI) | Active, not recruiting --> Recruiting
    Enrollment open
    |
    RAD51 (RAD51 Homolog A)
    |
    alphalex-exatecan (CBX-12)
    3d
    TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma. (PubMed, World J Urol)
    Our findings underscore the clinical significance of TROP2 expression in UTUC and suggest that IHC-based evaluation may contribute to prognostic risk stratification.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    FGFR3 mutation
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3d
    Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. (PubMed, Int J Mol Sci)
    In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.
    Review • Journal • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • HER-2 amplification • BRAF V600 • RET fusion
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    3d
    The Influence of Molecular Factors on the Effectiveness of New Therapies in Endometrial Cancer-Latest Evidence and Clinical Trials. (PubMed, Cancers (Basel))
    This classification (refined in ProMisE and TransPORTEC) enables precise treatment: immunotherapy (pembrolizumab, dostarlimab) works excellently in dMMR/MSI-H tumors, PI3K/AKT/mTOR inhibitors and trastuzumab deruxtecan in selected molecular subtypes, and hormone therapy in ER-positive tumors. Integrating the molecular profile with FIGO allows for truly personalized treatment, although MMRp/MSS tumors remain a challenge. The future lies in multi-omics, new biomarkers, and combination therapies.
    Review • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • MSI (Microsatellite instability)
    |
    ER positive • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Jemperli (dostarlimab-gxly)